These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 15603248

  • 1. The evolution of antimicrobial agents used for the management of CARTIs: a focus on a new class of antimicrobials--the ketolides.
    Sbarbaro JA.
    Am J Manag Care; 2004 Oct; 10(12 Suppl):S389-99. PubMed ID: 15603248
    [No Abstract] [Full Text] [Related]

  • 2. Clinical and economic outcomes in the treatment of lower respiratory tract infections.
    Brixner DI.
    Am J Manag Care; 2004 Oct; 10(12 Suppl):S400-7. PubMed ID: 15603249
    [No Abstract] [Full Text] [Related]

  • 3. PROTEKT years 1-3 (1999-2002): study design and methodology.
    Harding I, Felmingham D.
    J Chemother; 2004 Dec; 16 Suppl 6():9-18. PubMed ID: 15690682
    [No Abstract] [Full Text] [Related]

  • 4. Cethromycin: a promising new ketolide antibiotic for respiratory infections.
    Rafie S, MacDougall C, James CL.
    Pharmacotherapy; 2010 Mar; 30(3):290-303. PubMed ID: 20180612
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Short-duration therapy for respiratory tract infections.
    Goff DA.
    Ann Pharmacother; 2004 Sep; 38(9 Suppl):S19-23. PubMed ID: 15226490
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
    Carter PL.
    Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
    [Abstract] [Full Text] [Related]

  • 11. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR.
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [Abstract] [Full Text] [Related]

  • 12. Prulifloxacin: a new antibacterial fluoroquinolone.
    Prats G, Rossi V, Salvatori E, Mirelis B.
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of ketolides on resistance selection and ecologic effects during treatment for respiratory tract infections.
    Nord CE, Farrell DJ, Leclercq R.
    Microb Drug Resist; 2004 Feb; 10(3):255-63. PubMed ID: 15383171
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Community-acquired bacterial respiratory tract infections.
    Brunton S, Carmichael B, Fitzgerald M, Liu H, Varon J, Weiland D.
    J Fam Pract; 2005 Mar; 54(3):255-62. PubMed ID: 15755379
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antimicrobial screening of Nicotiana tobacum on organisms isolated from patients with respiratory tract infection.
    Adeleye IA, Uwagboe UC.
    West Indian Med J; 2003 Dec; 52(4):325-6. PubMed ID: 15040073
    [No Abstract] [Full Text] [Related]

  • 20. Synthesis and antibacterial activity of 6-O-arylpropargyl-9-oxime-11,12-carbamate ketolides.
    Beebe X, Yang F, Bui MH, Mitten MJ, Ma Z, Nilius AM, Djuric SW.
    Bioorg Med Chem Lett; 2004 May 17; 14(10):2417-21. PubMed ID: 15109624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.